HealthMore in Health→
Ivonescimab Plus Chemotherapy Shows Promise in Advanced Triple-Negative Breast Cancer
Key Takeaways
- Ivonescimab is a PD-1/VEGF bispecific antibody.
- Phase 2 trial enrolled 36 patients with advanced TNBC.
- Objective response rate was 80.0%.
- Treatment-related adverse events occurred in all patients, but no deaths.
DE
DT Editorial Team··via nature.com
